339 related articles for article (PubMed ID: 12656747)
41. Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.
Copland M; Fraser AR; Harrison SJ; Holyoake TL
Cancer Immunol Immunother; 2005 Apr; 54(4):297-306. PubMed ID: 15692843
[TBL] [Abstract][Full Text] [Related]
42. Promising clinical trials on kinase inhibitor.
de Boer J
Trends Cell Biol; 2001 Mar; 11(3):110. PubMed ID: 11306264
[No Abstract] [Full Text] [Related]
43. Does presence of complex translocations involving BCR::ABL1 in chronic myeloid leukemia affect the response rate to tyrosine kinase inhibitors? A systematic review of the literature.
Sharma D; Wilson C; Kumar S; Ghose S; Sahoo R; Sharawat SK
Ann Diagn Pathol; 2024 Aug; 71():152303. PubMed ID: 38636337
[TBL] [Abstract][Full Text] [Related]
44. An update on chronic myeloid leukaemia.
Stark G; O'Brien SG
Clin Med (Lond); 2001; 1(5):354-7. PubMed ID: 11706876
[TBL] [Abstract][Full Text] [Related]
45. Early lymphoid blastic crisis following major karyotypic conversion in a chronic myeloid leukemia patient treated with interferon-alpha.
Ambrosetti A; Krampera M; Veneri D; Meneghini V; Aprili F; Martinelli G; Pizzolo G; Perona G
Int J Clin Lab Res; 1994; 24(1):58-9. PubMed ID: 8180425
[TBL] [Abstract][Full Text] [Related]
46. Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon-alpha combined with hydroxyurea.
Jehn U; Heinemann V
Cancer Detect Prev; 1998; 22(3):258-64. PubMed ID: 9618049
[TBL] [Abstract][Full Text] [Related]
47. Epigenetic Modulation of DDIT3 and MGMT Expression Acts Synergistically with Resistance to Imatinib towards CML Disease Progression: A Hospital based Study.
Hazarika G; Kalita MJ; Kalita S; Das PP; Dutta K; Lahkar L; Rajkonwar A; Idris MG; Khamo V; Kusre G; Medhi S
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4059-4069. PubMed ID: 38156838
[TBL] [Abstract][Full Text] [Related]
48. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shah NP; Bhatia R; Altman JK; Amaya M; Begna KH; Berman E; Chan O; Clements J; Collins RH; Curtin PT; DeAngelo DJ; Drazer M; Maness L; Metheny L; Mohan S; Moore JO; Oehler V; Pratz K; Pusic I; Rose MG; Shomali W; Smith BD; Styler M; Talpaz M; Tanaka TN; Tantravahi S; Thompson J; Tsai S; Vaughn J; Welborn J; Yang DT; Sundar H; Gregory K
J Natl Compr Canc Netw; 2024 Feb; 22(1):43-69. PubMed ID: 38394770
[TBL] [Abstract][Full Text] [Related]
49. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Baccarani M; Deininger MW; Rosti G; Hochhaus A; Soverini S; Apperley JF; Cervantes F; Clark RE; Cortes JE; Guilhot F; Hjorth-Hansen H; Hughes TP; Kantarjian HM; Kim DW; Larson RA; Lipton JH; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Pane F; Radich JP; Rousselot P; Saglio G; Saußele S; Schiffer C; Silver R; Simonsson B; Steegmann JL; Goldman JM; Hehlmann R
Blood; 2013 Aug; 122(6):872-84. PubMed ID: 23803709
[TBL] [Abstract][Full Text] [Related]
50. Autologous transplantation therapy for chronic myelogenous leukemia.
Bhatia R; Verfaillie CM; Miller JS; McGlave PB
Blood; 1997 Apr; 89(8):2623-34. PubMed ID: 9108379
[No Abstract] [Full Text] [Related]
51. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.
Cortes J; Hochhaus A; Hughes T; Kantarjian H
J Clin Oncol; 2011 Feb; 29(5):524-31. PubMed ID: 21220597
[TBL] [Abstract][Full Text] [Related]
52. Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-alpha.
Yanagisawa K; Yamauchi H; Kaneko M; Kohno H; Hasegawa H; Fujita S
Blood; 1998 Jan; 91(2):641-8. PubMed ID: 9427720
[TBL] [Abstract][Full Text] [Related]
53. A case of chronic myelogenous leukemia with T lymphoblastic and megakaryoblastic mixed crisis.
Iwamasa K; Yasukawa M; Fujita S
Jpn J Med; 1989; 28(1):89-95. PubMed ID: 2542679
[TBL] [Abstract][Full Text] [Related]
54. Detection by enzymatic amplification of bcr-abl mRNA in peripheral blood and bone marrow cells of patients with chronic myelogenous leukemia.
Lange W; Snyder DS; Castro R; Rossi JJ; Blume KG
Blood; 1989 May; 73(6):1735-41. PubMed ID: 2496773
[TBL] [Abstract][Full Text] [Related]
55. Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome.
Chandra HS; Heisterkamp NC; Hungerford A; Morrissette JJ; Nowell PC; Rowley JD; Testa JR
Cancer Genet; 2011 Apr; 204(4):171-9. PubMed ID: 21536234
[TBL] [Abstract][Full Text] [Related]
56. Trial of IFN or STI571 before proceeding to allografting for CML?
Hehlmann R
Leukemia; 2000 Sep; 14(9):1560-2. PubMed ID: 10995000
[TBL] [Abstract][Full Text] [Related]
57. Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis.
Collins SJ; Groudine MT
Blood; 1987 Mar; 69(3):893-8. PubMed ID: 3545323
[TBL] [Abstract][Full Text] [Related]
58. Chronic myeloid leukemia.
Deininger MW; Goldman JM
Curr Opin Hematol; 1998 Jul; 5(4):302-8. PubMed ID: 9747637
[TBL] [Abstract][Full Text] [Related]
59. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
Horne GA; Stobo J; Kelly C; Mukhopadhyay A; Latif AL; Dixon-Hughes J; McMahon L; Cony-Makhoul P; Byrne J; Smith G; Koschmieder S; BrÜmmendorf TH; Schafhausen P; Gallipoli P; Thomson F; Cong W; Clark RE; Milojkovic D; Helgason GV; Foroni L; Nicolini FE; Holyoake TL; Copland M
Leukemia; 2020 Jul; 34(7):1775-1786. PubMed ID: 31925317
[TBL] [Abstract][Full Text] [Related]
60. Identification of E6A2 BCR-ABL fusion in a Philadelphia-positive CML.
Dupont M; Jourdan E; Chiesa J
Leukemia; 2000 Nov; 14(11):2011-2. PubMed ID: 11069039
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
